Latest Conference Articles

November 10th 2017, 12:44am

PER® Chemotherapy Foundation Symposium (CFS)

PARP inhibitors offer exciting opportunities to improve outcomes for patients with ovarian cancer and hopefully will be moved to the front-line setting if the evidence warrants it, said Susana M. Campos, MD.

November 10th 2017, 12:18am

PER® Chemotherapy Foundation Symposium (CFS)

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ongoing roles of regorafenib (Stivarga) and TAS-102 (Lonsurf) in colorectal cancer (CRC) treatment.

November 9th 2017, 11:06pm

PER® Chemotherapy Foundation Symposium (CFS)

There is a great need—and opportunity—to improve ovarian cancer outcomes by understanding the immune milieu of ovarian cancers and harnessing the power of immunotherapy.

November 9th 2017, 10:58pm

PER® Chemotherapy Foundation Symposium (CFS)

The tumor-site agnostic FDA approval of the PD-1 inhibitor pembrolizumab (Keytruda) for patients with microsatellite instability-high or mismatch repair deficient solid tumors has helped propel endometrial cancer into the immunotherapy age.

November 9th 2017, 7:00pm

ESGO Congress

Umesh Mahantshetty, MD, shares his insight on the state of cervical cancer treatment in developing countries.

November 9th 2017, 2:47am

PER® Chemotherapy Foundation Symposium (CFS)

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ongoing role and impact of regorafenib (Stivarga) in the paradigm of hepatocellular carcinoma (HCC) in an interview during the 2017 Chemotherapy Foundation Symposium.

November 9th 2017, 2:34am

PER® Chemotherapy Foundation Symposium (CFS)

As clinicians’ understanding of the disease pathobiology associated with Hodgkin lymphoma (HL) has increased, novel treatments have emerged.

November 9th 2017, 1:48am

PER® Chemotherapy Foundation Symposium (CFS)

Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses updates to the treatment paradigm of high-risk multiple myeloma in an interview during the 2017 Chemotherapy Foundation Symposium.

November 9th 2017, 1:33am

PER® Chemotherapy Foundation Symposium (CFS)

The next frontier in advancing the field of chronic lymphocytic leukemia (CLL) is identifying patients who will not experience long-term progression-free survival on novel agents.

November 9th 2017, 1:32am

PER® Chemotherapy Foundation Symposium (CFS)

Because genetic abnormalities play a role in multiple myeloma, it is important to understand these better to improve outcomes, particularly for high-risk patients, said Shaji K. Kumar, MD.

November 9th 2017, 12:36am

ESGO Congress

Maintenance therapy with olaparib monotherapy provides clinically significant, long-term treatment benefits and is safe in patients with platinum-sensitive relapsed serous ovarian cancer.

November 8th 2017, 9:45pm

ESGO Congress

Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses ataxia–telangiectasia and Rad3 related (ATR) inhibitors in patients with ovarian cancer who have BRCA-mutated tumors.

November 8th 2017, 9:44pm

ESGO Congress

Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, discusses the role of imaging in the diagnosis of endometrial cancer.

November 8th 2017, 9:44pm

ESGO Congress

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the results of the ARIEL3 trial in ovarian cancer.

November 8th 2017, 9:44pm

ESGO Congress

Xavier Bosch, MD, MPH, Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia–Catalan Institute of Oncology, introduces a second-generation vaccination against the human papilloma virus (HPV) for the prevention of cervical cancer.

November 8th 2017, 9:00pm

ESGO Congress

Jonathan Ledermann, MD, discussed these results, as well as the future of PARP inhibitors in the maintenance setting for patients with ovarian cancer.

November 8th 2017, 8:00pm

ESGO Congress

Patients with ovarian cancer were unified in their responses regardless of age, disease stage, or whether they had primary or recurrent disease, and were more likely to opt to receive maintenance therapy if it could offer delay of disease progression and allow patients to maintain or improve their quality of life.

November 8th 2017, 6:58pm

ESGO Congress

Deleterious mutations in the PALB2 gene may account for the development of breast cancer in women with an elevated risk due to a family history of breast or ovarian cancer, but who test negative for the BRCA1 or BRCA2 genes.

November 8th 2017, 1:50am

ESGO Congress

Rucaparib delayed disease recurrence in the intent to treat population and across subgroups of women with ovarian cancer.

November 8th 2017, 12:58am

ESGO Congress

Jalid Sehouli, MD, PhD, discusses the significance of these findings in the treatment of patients with platinum-sensitive recurrent ovarian cancer.